%0 Journal Article
%T Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review.
%A Koczanowski S
%A Morrisroe K
%A Fairley J
%A Nikpour M
%A Oon S
%A Brown Z
%J Semin Arthritis Rheum
%V 68
%N 0
%D 2024 Jun 22
%M 38954999
%F 5.431
%R 10.1016/j.semarthrit.2024.152471
%X <B>BACKGROUND: </B>Systemic sclerosis (SSc) is a heterogenous, multi-system autoimmune disease that causes progressive fibrosis of the skin and internal organs, resulting in high morbidity and mortality. Intravenous Immunoglobulin (IVIG) is a therapeutic option for SSc; however, reports of its efficacy have been variable, and its use across multiple organ manifestations of SSc has not been comprehensively reviewed.<BR><B>OBJECTIVE: </B>The aim of this study was to systematically assess the existing literature on the role of IVIG use across a range of SSc manifestations.<BR><B>METHODS: </B>Medline, Embase, Cochrane, Web of Science and Scopus were searched from 01/01/2003-15/04/2024 using terms related to SSc and IVIG. Included studies were English-language full texts, where ≥5 adults with SSc received IVIG, and where a reportable outcome was documented.<BR><B>RESULTS: </B>Of 418 potentially relevant records, 12 were included in this review, comprising 266 patients across one randomised control trial, two pilot studies, one open label study, seven retrospective studies and one case control study. Eighteen outcomes were documented across five different organ systems: cutaneous, respiratory, musculoskeletal, gastrointestinal, and other (clinical improvement and corticosteroid sparing benefit). Results showed a favourable effect of IVIG in reducing the extent of skin thickening, muscle and joint pain, gastrointestinal symptoms, steroid dosing and improving patient/physician reported quality of life. Whilst IVIG may appear to be less beneficial for respiratory disease, the stabilisation in pulmonary function tests and radiological features may be considered a positive outcome in itself. Limitations included a lack of high-quality studies, and the use of concomitant therapies in many studies, rendering the efficacy of IVIG alone difficult to ascertain.<BR><B>CONCLUSIONS: </B>IVIG showed benefit in treating some manifestations of SSc, however there was a lack of convincing evidence for the efficacy in others. The lack of high-quality data highlights the need for further well-designed clinical trials to confirm these findings and inform guidelines for IVIG use.